A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food Effect of AMG 357 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2015
Price : $35 *
At a glance
- Drugs AMG 357 (Primary)
- Indications Inflammation
- Focus Adverse reactions
- Sponsors Amgen
- 03 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 31 Jul 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Sep 2014 to 1 Oct 2014.
- 06 May 2014 Planned End Date changed from 1 Jun 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.